Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

Targeting angiogenesis in glioblastoma (GBM) may improve patient outcome by normalizing tumor vasculature and improving delivery of chemotherapeutics and oxygen. Consequently, concomitant administration of small molecule inhibitors of the VEGF pathway will likely have a positive impact on chemoradia...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Gerstner, Elizabeth R., Eichler, April F., Plotkin, Scott R., Drappatz, Jan, Doyle, Colin L., Xu, Lei, Duda, Dan G., Wen, Patrick Y., Jain, Rakesh K., Batchelor, Tracy T.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2010
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4090923/
https://ncbi.nlm.nih.gov/pubmed/20821342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0390-7
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk